Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010194713> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2010194713 endingPage "587" @default.
- W2010194713 startingPage "587" @default.
- W2010194713 abstract "DirectorAcute Pain ServiceAssociate Professor of AnesthesiologyBaystate Medical Center and the Tufts University School of Medicine Springfield, Massachusettsscott.reuben@bhs.orgIn Reply:—Although we agree that this patient was at increased risk for development of gastropathy because of her older age and history of peptic ulcer disease, we did not believe this was a contraindication to the use of celecoxib. Although the package insert for celecoxib 1states that “significant upper GI bleeding” has occurred with celecoxib, the reported incidence was only 2 of 5,285 (0.04%) patients. In addition, a randomized controlled study 2that evaluated the safety and efficiency of 200–800 mg/day celecoxib compared with 1,000 mg/day naproxen or with placebo revealed no statistically significant differences in the incidence of gastroduodenal ulcers between the placebo group and any of the celecoxib groups (P > 0.40). In contrast, the incidence of ulceration in the naproxen group was significantly greater than in each of the other treatment groups (P < 0.001). Patients who were elderly or had a history of peptic ulcer disease were not excluded from this study. In fact, neither of these risk factors was associated with an increased risk for ulceration in any of the celecoxib groups. Therefore, we believed that celecoxib was a safer alternative to naproxen for our patient who received excellent analgesia from previous nonsteroidal antiinflammatory drug (NSAID) therapy.In addition, we elected to administer omeprazole in conjunction with celecoxib therapy to facilitate gastric healing. The healing effectiveness of omeprazole does not appear to be compromised by the continued use of NSAIDs. 3Despite these measures, a gastric perforation still developed in our patient. As discussed in our case report, 4we believe that blocking the production of prostaglandins derived from COX-2 may be deleterious in the setting of a recent gastric mucosal injury. The previous cited studies 1,2that evaluated the risk of gastrointestinal tract ulceration during the administration of celecoxib did not include patients with a recent history (≤ 30 days) of peptic ulcer disease.Although we believe COX-2 inhibitors are safer alternatives to standard NSAIDs in the presence of peptic ulcer disease, perhaps alternative analgesic therapy should be initiated in the presence of a recent gastroduodenal ulcer." @default.
- W2010194713 created "2016-06-24" @default.
- W2010194713 creator A5064391122 @default.
- W2010194713 date "2000-08-01" @default.
- W2010194713 modified "2023-09-25" @default.
- W2010194713 title "Gastropathy and NSAIDs" @default.
- W2010194713 doi "https://doi.org/10.1097/00000542-200008000-00056" @default.
- W2010194713 hasPublicationYear "2000" @default.
- W2010194713 type Work @default.
- W2010194713 sameAs 2010194713 @default.
- W2010194713 citedByCount "0" @default.
- W2010194713 crossrefType "journal-article" @default.
- W2010194713 hasAuthorship W2010194713A5064391122 @default.
- W2010194713 hasConcept C120665830 @default.
- W2010194713 hasConcept C121332964 @default.
- W2010194713 hasConcept C126322002 @default.
- W2010194713 hasConcept C141071460 @default.
- W2010194713 hasConcept C142724271 @default.
- W2010194713 hasConcept C204787440 @default.
- W2010194713 hasConcept C27081682 @default.
- W2010194713 hasConcept C2776467144 @default.
- W2010194713 hasConcept C2776494729 @default.
- W2010194713 hasConcept C2777498785 @default.
- W2010194713 hasConcept C2778115740 @default.
- W2010194713 hasConcept C61511704 @default.
- W2010194713 hasConcept C71924100 @default.
- W2010194713 hasConcept C90924648 @default.
- W2010194713 hasConceptScore W2010194713C120665830 @default.
- W2010194713 hasConceptScore W2010194713C121332964 @default.
- W2010194713 hasConceptScore W2010194713C126322002 @default.
- W2010194713 hasConceptScore W2010194713C141071460 @default.
- W2010194713 hasConceptScore W2010194713C142724271 @default.
- W2010194713 hasConceptScore W2010194713C204787440 @default.
- W2010194713 hasConceptScore W2010194713C27081682 @default.
- W2010194713 hasConceptScore W2010194713C2776467144 @default.
- W2010194713 hasConceptScore W2010194713C2776494729 @default.
- W2010194713 hasConceptScore W2010194713C2777498785 @default.
- W2010194713 hasConceptScore W2010194713C2778115740 @default.
- W2010194713 hasConceptScore W2010194713C61511704 @default.
- W2010194713 hasConceptScore W2010194713C71924100 @default.
- W2010194713 hasConceptScore W2010194713C90924648 @default.
- W2010194713 hasIssue "2" @default.
- W2010194713 hasLocation W20101947131 @default.
- W2010194713 hasOpenAccess W2010194713 @default.
- W2010194713 hasPrimaryLocation W20101947131 @default.
- W2010194713 hasRelatedWork W1968728403 @default.
- W2010194713 hasRelatedWork W1975457186 @default.
- W2010194713 hasRelatedWork W1990986050 @default.
- W2010194713 hasRelatedWork W1991350847 @default.
- W2010194713 hasRelatedWork W2010356890 @default.
- W2010194713 hasRelatedWork W2050532333 @default.
- W2010194713 hasRelatedWork W2054305086 @default.
- W2010194713 hasRelatedWork W2055841596 @default.
- W2010194713 hasRelatedWork W2073480881 @default.
- W2010194713 hasRelatedWork W2140790966 @default.
- W2010194713 hasVolume "93" @default.
- W2010194713 isParatext "false" @default.
- W2010194713 isRetracted "false" @default.
- W2010194713 magId "2010194713" @default.
- W2010194713 workType "article" @default.